Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine
about
Recombinant bactericidal/permeability-increasing protein rBPI21 protects against pneumococcal diseaseVaccines for Pseudomonas aeruginosa: a long and winding roadThe galU Gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung.Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant.MicroRNA-302b augments host defense to bacteria by regulating inflammatory responses via feedback to TLR/IRAK4 circuits.Design of live attenuated bacterial vaccines based on D-glutamate auxotrophy.Th17 cytokines and vaccine-induced immunity.Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumoniaA live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.Functional characterization of Edwardsiella tarda twin-arginine translocation system and its potential use as biological containment in live attenuated vaccine of marine fish.Host DNA repair proteins in response to Pseudomonas aeruginosa in lung epithelial cells and in mice.Attenuation and persistence of and ability to induce protective immunity to a Staphylococcus aureus aroA mutant in mice.Elevated inflammatory response in caveolin-1-deficient mice with Pseudomonas aeruginosa infection is mediated by STAT3 protein and nuclear factor kappaB (NF-kappaB)Transient Receptor Potential Channel 1 Deficiency Impairs Host Defense and Proinflammatory Responses to Bacterial Infection by Regulating Protein Kinase Cα Signaling.Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.Annexin A2 Regulates Autophagy in Pseudomonas aeruginosa Infection through the Akt1-mTOR-ULK1/2 Signaling PathwayPseudomonas aeruginosa: the potential to immunise against infection.Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.Collaboration between macrophages and vaccine-induced CD4+ T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia.A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy.Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa.Pseudomonas aeruginosa infection augments inflammation through miR-301b repression of c-Myb-mediated immune activation and infiltration.Exogenous remodeling of lung resident macrophages protects against infectious consequences of bone marrow-suppressive chemotherapy.Recent developments for Pseudomonas vaccines.A D-Alanine Auxotrophic Live Vaccine is Effective against Lethal Infection Caused by Staphylococcus aureus.Lyn prevents aberrant inflammatory responses to infection in mammalian systems by repressing a SHIP-1-associated signaling cluster
P2860
Q24678809-8D215496-69C7-4119-98AF-19F2739F589CQ26852817-FE90BAA6-029F-41A4-92E3-A7190A5E36BBQ28492530-D76C8718-3E74-4833-B1BE-8D9F533011CFQ30430870-DF2E9292-438A-42EE-80D6-2173A83DEE48Q30435195-32BE6EB9-FD8D-4194-A241-D0D8DF6D161CQ30438358-85AB47FD-D778-4C43-8342-7B3AB4CA3D08Q30453151-CF7CE6A6-2CCF-405F-8BF1-20E3362CAC56Q33572152-29ED5318-4160-40FF-ACCC-8EBE0A9DDEF3Q33763029-B24BE553-A25D-4804-A55A-CA26C7AB4035Q33792227-DD472D88-E03A-4239-9EF1-CFD92762588EQ34313640-5B69B41F-C150-4E10-ADC9-9E4787B1AB28Q34334168-8EBBA211-A623-44DB-8A68-5629229A2C02Q34439836-7372CABC-8D3E-48BF-BCFF-A695F83D1B4AQ34484711-6FDECE9C-ADEA-4DF2-9F72-1DA0366BF7B7Q34681033-85A9F8CD-A183-41E4-BF31-09545E721194Q35065271-2D1AB7EE-EE52-40EA-BC4D-218405E35F62Q35868419-9657DE1F-F25B-406E-8E20-F239C55D9028Q36013525-B5451D38-05C2-4268-8FB0-FB576D22ECA9Q36119446-02D5C2BD-2049-4146-8BFB-01F671D7380BQ36194089-B96BE34B-7C80-4F33-8123-BA7F28A3299CQ36284542-2C5FAEF0-69D4-4E05-8952-6719AF93974AQ36471098-61169DC4-96F7-4C82-977F-6AC9FBDC3B77Q36883886-0E486B22-FA46-4D2C-9417-FAABFA3BACE3Q37298019-11B253DF-5BE3-40A9-80F1-2334F28D0869Q37334199-D3709C3F-2FC3-4D33-B948-6E28B2755B0AQ37346941-87579489-831A-4CB8-8848-4280FD79602CQ37937369-05B1E256-E209-423D-9A97-5F76775235D0Q48551373-B49FC6AC-6CDE-4017-B005-47A8BCE58609Q57752587-639399DE-9287-4542-A56D-EBFFF42DB832
P2860
Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Construction and characterizat ...... a candidate intranasal vaccine
@ast
Construction and characterizat ...... a candidate intranasal vaccine
@en
type
label
Construction and characterizat ...... a candidate intranasal vaccine
@ast
Construction and characterizat ...... a candidate intranasal vaccine
@en
prefLabel
Construction and characterizat ...... a candidate intranasal vaccine
@ast
Construction and characterizat ...... a candidate intranasal vaccine
@en
P2093
P2860
P1476
Construction and characterizat ...... a candidate intranasal vaccine
@en
P2093
Fadie T Coleman
Gregory P Priebe
Joanna B Goldberg
Kazue Hatano
Martha Grout
Mary M Brinig
P2860
P304
P356
10.1128/IAI.70.3.1507-1517.2002
P407
P50
P577
2002-03-01T00:00:00Z